Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study

被引:132
|
作者
Pearce, Lindsay A. [1 ]
Min, Jeong Eun [1 ]
Piske, Micah [1 ]
Zhou, Haoxuan [1 ]
Homayra, Fahmida [1 ]
Slaunwhite, Amanda [2 ]
Irvine, Mike [2 ]
McGowan, Gina [3 ]
Nosyk, Bohdan [1 ,4 ]
机构
[1] British Columbia Ctr Excellence HIV AIDS, Hlth Econ Res Unit, Vancouver, BC V6Z 1Y6, Canada
[2] British Columbia Ctr Dis Control & Prevent, Vancouver, BC V5Z 4R4, Canada
[3] British Columbia Minist Mental Hlth & Addict, Victoria, BC V8W 9P1, Canada
[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada
来源
BMJ-BRITISH MEDICAL JOURNAL | 2020年 / 368卷
关键词
PHARMACOLOGICAL-TREATMENT; METHADONE; DRUG; BUPRENORPHINE; DEPENDENCE; HEROIN; THERAPY;
D O I
10.1136/bmj.m772
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To compare the risk of mortality among people with opioid use disorder on and off opioid agonist treatment (OAT) in a setting with a high prevalence of illicitly manufactured fentanyl and other potent synthetic opioids in the illicit drug supply. Design - Population based retrospective cohort study. Setting - Individual level linkage of five health administrative datasets capturing drug dispensations, hospital admissions, physician billing records, ambulatory care reports, and deaths in British Columbia, Canada. Participants - 55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018. Main outcome measures - All cause and cause specific crude mortality rates (per 1000 person years) to determine absolute risk of mortality and all cause age and sex standardised mortality ratios to determine relative risk of mortality compared with the general population. Mortality risk was calculated according to treatment status (on OAT, off OAT), time since starting and stopping treatment (1, 2, 3-4, 5-12, >12 weeks), and medication type (methadone, buprenorphine/naloxone). Adjusted risk ratios compared the relative risk of mortality on and off OAT over time as fentanyl became more prevalent in the illicit drug supply. Results- 7030 (12.7%) of 55 347 OAT recipients died during follow-up. The all cause standardised mortality ratio was substantially lower on OAT (4.6, 95% confidence interval 4.4 to 4.8) than off OAT (9.7, 9.5 to 10.0). In a period of increasing prevalence of fentanyl, the relative risk of mortality off OAT was 2.1 (95% confidence interval 1.8 to 2.4) times higher than on OAT before the introduction of fentanyl, increasing to 3.4 (2.8 to 4.3) at the end of the study period (65% increase in relative risk). Conclusions - Retention on OAT is associated with substantial reductions in the risk of mortality for people with opioid use disorder. The protective effect of OAT on mortality increased as fentanyl and other synthetic opioids became common in the illicit drug supply, whereas the risk of mortality remained high off OAT. As fentanyl becomes more widespread globally, these findings highlight the importance of interventions that improve retention on opioid agonist treatment and prevent recipients from stopping treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study
    Morrow, Richard L.
    Bassett, Ken
    Maclure, Malcolm
    Dormuth, Colin R.
    BMJ OPEN, 2019, 9 (05):
  • [42] What is the ideal time to begin tapering opioid agonist treatment? A protocol for a retrospective population-based comparative effectiveness study in British Columbia, Canada
    Yan, Ruyu
    Kurz, Megan
    Guerra-Alejos, B. Carolina
    Min, Jeong Eun
    Bach, Paxton
    Greenland, Sander
    Gustafson, Paul
    Karim, Ehsan
    Korthuis, P. Todd
    Loughin, Tom
    McCandless, Lawrence
    Platt, Robert W.
    Schnepel, Kevin
    Seaman, Shaun
    Socias, M. Eugenia
    Wood, Evan
    Xie, Hui
    Nosyk, Bohdan
    BMJ OPEN, 2024, 14 (04):
  • [43] Short term health-related quality of life improvement during opioid agonist treatment
    Nosyk, B.
    Bray, J. W.
    Wittenberg, E.
    Aden, B.
    Eggman, A. A.
    Weiss, R. D.
    Potter, J.
    Ang, A.
    Hser, Y. -I.
    Ling, W.
    Schackman, B. R.
    DRUG AND ALCOHOL DEPENDENCE, 2015, 157 : 121 - 128
  • [44] Predicting opioid overdose risk of patients with opioid prescriptions using electronic health records based on temporal deep learning
    Dong, Xinyu
    Deng, Jianyuan
    Hou, Wei
    Rashidian, Sina
    Rosenthal, Richard N.
    Saltz, Mary
    Saltz, Joel H.
    Wang, Fusheng
    JOURNAL OF BIOMEDICAL INFORMATICS, 2021, 116
  • [45] Risk of drug-related death associated with co-prescribing of gabapentinoids and Z-drugs among people receiving opioid-agonist treatment: A national retrospective cohort study
    Glancy, Megan
    Palmateer, Norah
    Yeung, Alan
    Hickman, Matthew
    Macleod, John
    Bishop, Jen
    Barnsdale, Lee
    Trayner, Kirsten M. A.
    Priyadarshi, Saket
    Wallace, Jason
    Hutchinson, Sharon
    McAuley, Andrew
    PSYCHIATRY RESEARCH, 2024, 339
  • [46] Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data
    Hartung, Daniel M.
    McCracken, Caitlin M.
    Nguyen, Thuan
    Kempany, Katherine
    Waddell, Elizabeth Needham
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2023, 147
  • [47] The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study
    Jones, Nicola R.
    Hickman, Matthew
    Nielsen, Suzanne
    Larney, Sarah
    Dobbins, Timothy
    Ali, Robert
    Degenhardt, Louisa
    DRUG AND ALCOHOL DEPENDENCE, 2022, 236
  • [48] A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome
    Sujan, Ayesha
    Cleary, Emma
    Douglas, Edie
    Aujla, Rubin
    Boyars, Lisa
    Smith, Claire
    Guille, Constance
    FAMILY PRACTICE, 2022, 39 (02) : 311 - 315
  • [49] Baseline Factors Associated with Mortality in Patients Who Engaged in Buprenorphine Treatment for Opioid Use Disorder: a Cohort Study
    Fine, Danielle R.
    Yu, Liyang
    Triant, Virginia A.
    Baggett, Travis P.
    Metlay, Joshua P.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (08) : 2375 - 2382
  • [50] Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment
    Rosic, Tea
    Naji, Leen
    Sanger, Nitika
    Marsh, David C.
    Worster, Andrew
    Thabane, Lehana
    Samaan, Zainab
    JOURNAL OF ADDICTION MEDICINE, 2022, 16 (04) : E257 - E264